[1] Endale H, Aliye S, Mathewos M. Vaccine epidemiology, evaluation, and constraints of vaccine effectiveness-a review. Vet Vaccine, 2022; 1, 100004. doi:  10.1016/j.vetvac.2022.100004
[2] World Health Organization. WHO guide on standardization of economic evaluations of immunization programmes. World Health Organization. 2019.
[3] Bloom DE, Brenzel L, Cadarette D, et al. Moving beyond traditional valuation of vaccination: needs and opportunities. Vaccine, 2017; 35, A29−35. doi:  10.1016/j.vaccine.2016.12.001
[4] Johnston A, Kelly SE, Hsieh SC, et al. Systematic reviews of clinical practice guidelines: a methodological guide. J Clin Epidemiol, 2019; 108, 64−76. doi:  10.1016/j.jclinepi.2018.11.030
[5] Postma M, Biundo E, Chicoye A, et al. Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts. Vaccine, 2022; 40, 3999−4007. doi:  10.1016/j.vaccine.2022.04.026
[6] Pollard SL, Malpica-Llanos T, Friberg IK, et al. Estimating the herd immunity effect of rotavirus vaccine. Vaccine, 2015; 33, 3795−800. doi:  10.1016/j.vaccine.2015.06.064
[7] Smith ER, Fry AM, Hicks LA, et al. Reducing antibiotic use in ambulatory care through influenza vaccination. Clin Infect Dis, 2020; 71, e726−34. doi:  10.1093/cid/ciaa464
[8] Tessmer A, Welte T, Schmidt-Ott R, et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J, 2011; 38, 147−53. doi:  10.1183/09031936.00133510
[9] Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med, 2006; 354, 1455−63. doi:  10.1056/NEJMoa051642
[10] Ma SY, Lavelle TA, Ollendorf DA, et al. Herd immunity effects in cost-effectiveness analyses among low- and middle-income countries. Appl Health Econ Health Policy, 2022; 20, 395−404. doi:  10.1007/s40258-021-00711-y
[11] Nymark LS, Sharma T, Miller A, et al. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine, 2017; 35, 6828−41. doi:  10.1016/j.vaccine.2017.10.024
[12] Jawad M, Naz M. Impact of covid-19 pandemic on macroeconomic aspects. J Open Innovation: Technol, Market, Complexity, 2023; 9, 100126. doi:  10.1016/j.joitmc.2023.100126
[13] Mateen QG, Raghav S, Kumar S, et al. The macroeconomic implications of COVID-19 economic crisis worldwide. In: Raghav A, Jeong GB, Ashraf H. COVID-19 Impact on Economy, Environment and Healthcare. Springer. 2025, 87-104.
[14] Sağlam Ü. Beyond GDP: COVID-19’s effects on macroeconomic efficiency and productivity dynamics in OECD countries. Econometrics, 2025; 13, 29−64. doi:  10.3390/econometrics13030029
[15] Beck E, Biundo E, Devlin N, et al. Capturing the value of vaccination within health technology assessment and health economics: literature review and novel conceptual framework. Vaccine, 2022; 40, 4008−16. doi:  10.1016/j.vaccine.2022.04.050
[16] Arsenault C, Gage A, Kim MK, et al. COVID-19 and resilience of healthcare systems in ten countries. Nat Med, 2022; 28, 1314−24. doi:  10.1038/s41591-022-01750-1
[17] Haldane V, De Foo C, Abdalla SM, et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med, 2021; 27, 964−80. doi:  10.1038/s41591-021-01381-y
[18] Zhai YQ, Han YZ, Wang WL, et al. Advancements in mpox vaccine development: a comprehensive review of global progress and recent data. Biomed Environ Sci, 2025; 38, 248−54.
[19] Riley AG, Voehler D, Mitrovich R, et al. Documenting the full value of vaccination: a systematic review of value frameworks. Value Health, 2024; 27, 1289−99. doi:  10.1016/j.jval.2024.04.022
[20] Riumallo-Herl C, Chang AY, Clark S, et al. Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study. BMJ Glob Health, 2018; 3, e000613. doi:  10.1136/bmjgh-2017-000613
[21] Bawah AA, Phillips JF, Adjuik M, et al. The impact of immunization on the association between poverty and child survival: evidence from Kassena-Nankana district of northern Ghana. Scand J Public Health, 2010; 38, 95−103. doi:  10.1177/1403494809352532
[22] Countdown 2008 Equity Analysis Group. Mind the gap: equity and trends in coverage of maternal, newborn, and child health services in 54 countdown countries. Lancet, 2008; 371, 1259−67. doi:  10.1016/S0140-6736(08)60560-7
[23] Bishaia D, Koenig M, Khan MA. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ, 2003; 12, 415−9. doi:  10.1002/hec.732
[24] Pike J, Tippins A, Nyaku M, et al. Cost of a measles outbreak in a remote island economy: 2014 federated states of micronesia measles outbreak. Vaccine, 2017; 35, 5905−11. doi:  10.1016/j.vaccine.2017.08.075
[25] Fajgenblat M, Molenberghs G, Verbeeck J, et al. Evaluating the direct effect of vaccination and non-pharmaceutical interventions during the COVID-19 pandemic in Europe. Commun Med, 2024; 4, 178−87. doi:  10.1038/s43856-024-00600-0
[26] Zhou LH, Yan WX, Li S, et al. Cost-effectiveness of interventions for the prevention and control of COVID-19: systematic review of 85 modelling studies. J Glob Health, 2022; 12, 05022. doi:  10.7189/jogh.12.05022
[27] Doroshenko A. The combined effect of vaccination and nonpharmaceutical public health interventions—ending the COVID-19 pandemic. JAMA Network Open, 2021; 4, e2111675. doi:  10.1001/jamanetworkopen.2021.11675